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For patients presenting with an acute ST-segment elevation myocardial infarction 
(STEMI), the most effective therapy for reducing myocardial infarct (MI) size and 
preserving left ventricular (LV) systolic function is primary percutaneous coronary 
intervention (PPCI). However, mortality and morbidity remain significant. This is 
partly attributed to the development of microvascular obstruction (MVO), which 
occurs in up to 50% of STEMI patients post-PPCI, and it is associated with adverse 
LV remodeling and worse clinical outcomes. Although MVO can be detected by 
cardiac imaging techniques several hours post-PPCI, it may be too late to intervene 
at that time. Therefore, being able to predict the development of MVO at the time of 
PPCI may identify high-risk patients who might benefit from further adjuvant 
intracoronary therapies such as thrombolysis, vasodilators, glycoprotein IIbIIIa 
inhibitors and anti-inflammatory agents that may reduce MVO. Recent studies have 
shown that invasive coronary physiology measurements performed during PPCI can 
be used to assess the coronary microcirculation. In this article, we provide an 
overview of the various invasive methods currently available to assess the coronary 
microcirculation in the setting of STEMI, and how they could potentially be used in 







Prompt restoration of blood flow in the occluded epicardial coronary artery by 
primary percutaneous coronary intervention (PPCI), following an acute ST-segment 
elevation myocardial infarction (STEMI), is currently the gold-standard therapy for 
reducing myocardial infarct (MI) size and preserving left ventricular (LV) systolic 
function1. However, although mortality due to STEMI has declined substantially since 
the introduction of PPCI, morbidity remains significant at one year.2 This has been 
partly attributed to the detrimental effects of prompt restoration of coronary blood flow 
to the acutely ischemic myocardium, which itself can induce coronary microvascular 
injury and cardiomyocyte death, a phenomenon termed ‘Reperfusion Injury (RI)’. 
There are 4 types of RI: myocardial stunning; reperfusion arrhythmias; coronary no 
reflow or microvascular obstruction (MVO); and ‘lethal myocardial reperfusion injury’3 
as illustrated in Figure 1. The first two are considered reversible, as they are usually 
transient or easily treated. To date, there is no effective therapy to prevent or 
minimize the burden of microvascular obstruction (MVO) and ‘lethal myocardial 
reperfusion injury’ and both are currently considered irreversible.  
The phenomenon of MVO was first described in 1966 and it refers to the 
inability to reperfuse a previously ischemic myocardium in the presence of a patent 
epicardial coronary artery.4 MVO occurs in up to 50% of STEMI patients following 
PPCI and is associated with adverse LV remodeling and worse clinical outcomes.5 
MVO can be detected at the time of PPCI by the presence of impaired myocardial 
blush grade (MBG) despite a patent epicardial coronary artery. It can be assessed 
non-invasively by electrocardiography, myocardial contrast echocardiography 
(MCE)6, myocardial scintigraphy7 and contrast-enhanced cardiovascular magnetic 
resonance (CMR)8 but these are typically performed a few hours or days post-PPCI. 
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 Recent studies have shown that invasive coronary physiology measurements 
acquired during PPCI may be used to assess the coronary microcirculation at the 
time of PPCI. This may allow early implementation of adjuvant therapies via the 
intracoronary route to reduce MVO, whilst the patient is still in the cardiac 
catheterization laboratory.  In this article, we provide an overview of the various 
invasive coronary physiology techniques to assess the coronary microcirculation in 
the setting of STEMI and explore their strengths and limitations, and how they could 
potentially be applied in the clinical setting to improve outcomes.  
 
THE DETERMINANTS AND CLINICAL SIGNIFANCE OF MVO 
Five major factors have been shown to contribute to the development of MVO 
namely9: pre-existing coronary microvascular dysfunction; the extent of ischemic 
injury; the presence of RI; distal coronary micro-embolization; and individual 
susceptibility (genetic factors such as 1976T.C polymorphism of the adenosine 2A 
receptors gene predisposing certain patients to the development of MVO; the 
presence of pre-infarct angina in certain patients may protect against the 
development of MVO)9. The pre-existence of coronary microvascular dysfunction and 
individual susceptibility are non-modifiable. The extent of ischemic injury is 
dependent on the symptom onset-to-door and door-to-balloon times, the area-at-risk, 
Thrombolysis in Myocardial Infarction (TIMI) flow pre-PPCI and collateral flow. Efforts 
have already been made to reduce the onset-to-balloon time to a minimum since the 
introduction of PPCI. Therefore, the main focus of research to minimize the burden of 
MVO has been to target both RI and distal coronary micro-embolization. A number of 
mechanisms have been described to contribute to the occurrence of MVO and these 
include external compression of capillaries by interstitial and/or cellular edema, by 
swollen cardiomyocytes and endothelial cells; the release of thrombogenic and 
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vasoactive substances; neutrophil plugging; capillary damage with extravasation of 
red blood cells (leading to intramyocardial hemorrhage - IMH); impaired coronary 
vasodilation; coronary micro-embolization from the atherosclerotic plaque, in-situ 
thrombosis and platelet micro-thrombi as illustrated in Figure 2.10 IMH has been 
shown to be a consequence of the process of reperfusion itself.11 MVO is closely 
linked with the development of IMH12 and clinical studies have supported the notion 
that MVO precedes the development of IMH in a subset of patients and is considered 
a more severe form of microvascular injury due to RI.13, 14  
The presence of MVO following PPCI as assessed by TIMI flow post-PPCI15, 
a combination of ST-segment resolution and MBG16, MCE 17 and CMR18 have all 
strongly been linked with worse outcomes.9 In a recent meta-analysis5 of more than 
1025 STEMI patients reperfused by PPCI and with a CMR performed within the first 
week, MVO was associated with the occurrence of a composite of cardiac death, 
congestive heart failure, and myocardial re-infarction with a hazard ratio of 3.74 (95% 
confidence interval of 2.21 to 6.34) whereas MI size was not, in a multivariate Cox 
regression analysis, after adjusting for confounders.  
Despite having a patent epicardial coronary artery post-PPCI, those patients 
with MVO have areas of ongoing hypoperfusion at the microcirculation level and 
achieving patency of the microcirculation may theoretically reduce MVO, prevent IMH 
and limit MI size. Recently, high dose intra-coronary adenosine and sodium 
nitroprusside failed to reduce MVO and MI size in a cohort of 247 reperfused STEMI 
patients.19 However 67% of those patients had MVO by CMR and it is likely that 
those drugs failed to reach the microcirculation in two third of the patients. Therefore, 
another approach that would more likely improve outcomes in these patients might 
be to identify those patients at risk of MVO at the time of PPCI and subject them to 
low dose intracoronary thrombolysis 20 first, to achieve patency of the 
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microcirculation, and they treated with an infusion of adenosine or sodium 
nitroprusside, that would then be more likely to reach the microcirculation.19  
 
 
NON-INVASIVE DETECTION ON MVO 
The current techniques for identifying MVO are mainly via non-invasive tests 
(summarized in Table 1) and these are usually performed 3-5 days post-PPCI, when 
it may be too late to intervene. Figure 3 shows an example of a patient with a left 
anterior descending coronary artery occlusion, reperfused by PPCI with TIMI flow 3, 
but with extensive areas of MVO (red arrows) on the delayed enhancement CMR 
images performed on day 3. This imaging modality cannot be performed in most 
centers immediately post-PPCI, and it may be too late to intervene by the time MVO 
is detected using this modality..  
The coronary microvascular circulation can also be assessed in the cardiac 
catheterization laboratory with TIMI flow grade22, corrected TIMI frame count 
(cTFC)23, TIMI myocardial perfusion grade (TMPG)24 and MBG22 (Table 1). However, 
these indexes are semi-quantitative and can be subjective25, although automated 
software are available.26 Furthermore, capillary permeability, microvascular spasm 
and capillary resistance under resting conditions may influence these indices.27 
Therefore, the utility and accuracy of these angiographic methods to detect MVO 
after primary PCI have limited their clinical application. 
INVASIVE ASSESSMENT OF THE CORONARY MICROCIRCULATION  
The coronary circulation can be divided into the epicardial vessels, the 
microcirculation and the venous circulation28 (Figure 2). Under normal resting 
physiological conditions, coronary blood flow is maintained at near constant levels 
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over a wide range of perfusion pressures by autoregulation.29 However, disturbances 
in the autoregulatory process and/or impaired microvascular vasodilatory function 
due to disruption in the coronary microcirculation occurring in the presence of 
prolonged ischemia and MVO can be detected by invasive measures of coronary 
microcirculation. This can be divided into flow-based and resistance-based 
parameters (although flow remains an important component in the derivation of the 
latter parameters) as below: 
1. Flow - based parameters 
a. Coronary flow velocity reserve (CFVR) 
b. Deceleration time of diastolic coronary flow velocity  
c. Presence of systolic flow reversal  
2. Resistance - based parameters 
a. Index of microvascular resistance (IMR) 
b. Hyperemic microvascular resistance (HMR) 
c. Coronary zero flow pressure (Pzf) 
 
Flow – based parameters 
a) Coronary flow velocity reserve  
CFVR is an index providing information on both the epicardial and coronary 
microvascular compartment. It can be derived by using both the Doppler29 and 
thermodilution30 techniques. CFVR is defined as the ratio of hyperemic to resting 
coronary blood flow.29 CFVR has been used to assess the coronary microcirculation 
in the absence of epicardial stenosis. CFVR can also be derived using the 
thermodilution principle [CFVR = Tmn at rest/ Tmn at hyperemia]30. A ratio of ≥ 2.0 is 
considered normal.8 A value of <2.0 has recently been shown to have a sensitivity of 
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79% for MVO and 80% for IMH but with a low specificity of 34% for the detection of 
both MVO and IMH in a large single-center study of 283 patients.8 
  Several studies have shown that CFVR measured in the reperfused infarct-
related artery to be a potential prognostic marker for LV recovery following STEMI31-
34 (online appendix Table 1). CFVR has also shown to correspond well with the 
extent of MVO by CMR35 and was found to be a better marker than TIMI flow, cTFC 
and MBG to predict recovery of LV function.34 An increase in CFVR from the end of 
PPCI to 24 hours later was associated with higher myocardial salvage index, 
whereas a reduction in CFVR at 24 hours was associated with MVO and IMH.36 A 
CFVR of <2.1 has also been shown to be associated with increased mortality at 10 
years.37    
b and c) Diastolic deceleration time and systolic flow reversal 
Rapid deceleration time of coronary diastolic flow velocity (diastolic deceleration time 
< 600 msec) and the presence of early systolic flow reversal in intracoronary Doppler 
recordings obtained after successful PPCI were shown to be associated with larger 
extent of MVO and poor long-term outcome after reperfusion.35, 38, 39 
Resistance – based parameters 
Intraluminal obstruction (athero-embolization, cellular and humoral factors etc.) in 
combination with extravascular compressive pathologies (edema and IMH) impact on 
the increase in microvascular resistance after successful reperfusion achieved by 
PPCI. Microvascular resistance indices (IMR, HMR and Pzf) are therefore extremely 
well suited to determine the extent of the microvascular impairment after PPCI where 
acute changes in microvascular resistance are expected to be the most dramatic. 
Moreover, these parameters are specific for the coronary microcirculation during 
peak hyperemia or zero flow assumptions and are less likely to be influenced by 
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hemodynamic perturbations such as microvascular tone and resistance40, heart 
rate41 and infusion of sodium nitroprusside and dobutamine.41  
a) Index of microvascular resistance (IMR) 
IMR is derived from the thermodilution principle42 using a guide wire with a 
pressure and a temperature sensor, and is defined as the distal coronary pressure 
(Pd) divided by the inverse of the mean transit time (Tmn) during hyperemia, or more 
simply, Pd multiplied by the Tmn (mm Hg · seconds, or units [U]).42 The wire sensor 
is usually positioned in the distal one third of the vessel (> 6cm from guide catheter 
tip). The average of 3 transit times of 3ml of room temperature normal saline solution 
during peak hyperemia is used to calculate Tmn43 and the variability among the 3 
readings should be <20%. An IMR value < 25U is indicative of normal microvascular 
perfusion.44  
IMR has been used as a surrogate to invasively assess the coronary 
microcirculation in STEMI patients for more than a decade (online appendix Table 1). 
High IMR values at the time of PPCI have been associated with larger MI size by 
cardiac enzymes45, less wall motion recovery at follow-up by echocardiography45, 46, 
less viability by 18F-fluorodeoxyglucose positron emission tomography (FDG PET). 
46 Factors predisposing to high IMR values have not been well studied but in a small 
study of 113 STEMI patients, Baek et al47 found age and symptom-to-balloon time to 
be major predictors of high IMR.  
Several studies have correlated IMR at the time of PPCI and CMR findings. 
Patients with high IMR were more likely to have MVO48-52, IMH53, larger MI size48, 
less myocardial salvage53 on the acute scan performed within a week and worse LV 
function at follow-up.48 However not all studies54, 55 have shown that the IMR at the 
end of the PPCI procedure could predict MVO on CMR and this was recently 
summarized in a meta-analysis of studies reporting mean IMR values only.56 These 
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studies individually were small and lacked power but after combining data from 6 
studies (246 patients) reporting mean IMR values, those with MVO had significantly 
higher IMR (49±33U, 99%CI 41-57U) than those without MVO (27±22U, 99%CI 22-
32U). In a recent single-center study of 283 patients by Carrick et al8, IMR was 
shown to be more closely associated with MVO, IMH and adverse LV remodeling by 
CMR and clinical outcomes than TMPG or CFR.  
Data on serial IMR measurements post-STEMI is limited. Sezer et al57 
showed that >33% improvement in IMR in the infarcted territory at 5 months was 
associated with a 50% reduction in MI size assessed by single photon emission 
computed tomography in a small cohort of 35 reperfused STEMI patients. Cuculi et 
al54 showed that, in 30 patients with CMR data at 6 months, those with MVO had a 
lower CFVR immediately post-PPCI and at 24 hours and a trend towards higher IMR. 
At 6 months, there was no difference in IMR and CFVR between these 2 groups of 
patients, despite a larger chronic MI size in the MVO group. However, unlike Sezer et 
al57, they did not explore the reduction in MI size in those with an improvement in 
IMR. Most recently, Hoole et al55 showed in 41 patients that those with an IMR <32U 
pre-stenting had a significant increase in IMR post-stenting and this was attributed to 
iatrogenic microvascular injury. Serial IMR measurements can improve our 
understanding of the microcirculation post-STEMI, but due to its invasive nature, 
getting patients back for repeat invasive measurements in the convalescent/chronic 
phase is challenging as highlighted by the Cuculi et al54 (almost half of the patients 
dropped out at 6 months). 
 Fukunaga et al52 (88 patients) found that the shape of the thermodilution-
derived temperature recovery curve following saline injection could be characterized 
into three categories. Patients in the “bimodal group” had higher prevalence of MVO 
on CMR and were at higher risk of death and rehospitalization for heart failure when 
compared to those in the “narrow unimodal” and “wide unimodal groups”. However 
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the impact of the speed of hand injections and the inter-observer reproducibility of 
these bimodal curves were not assessed and needs further validation.  
Another approach explored by Park et al58 (89 patients) has been to stratify 
STEMI patients according to both IMR and CFVR values. They found that those 
patients with CFVR<2 and IMR>27U did not show an improvement in wall motion 
score index by echocardiography. Ahn et al50 (40 patients) showed that a combined 
high IMR (>36U) and low CFVR (<1.7) were highly predictive of MVO by CMR after 
PPCI. However, Carrick et al59 recently showed that combining IMR >40U with CFR 
≤2.0 did not add prognostic value in 283 patients. All these 3 studies used different 
cut-off values for IMR and CFR and although Carrick et al59 had the largest number 
of patients, it was not powered for clinical outcomes.  
The effect of IMR on clinical outcomes post-PPCI has been investigated in a 
large multi-center study of 253 STEMI patients. Fearon et al60 found that patients 
with an IMR >40U, measured immediately after PPCI, was the only independent 
predictor of death (hazard ratio 4.3, P 0.02) after a median follow-up of 2.8 years. A 
recent meta-analysis56 showed that patients with an IMR >41U at the end of the 
PPCI procedure were more likely to have MVO on the CMR. Most recently, in a 
single-center study of 283 STEMI patients, Carrick et al59 also showed that an IMR 
>40U was a multivariable associate of adverse LV remodeling by CMR at 6 months, 
and was a better predictor of all-cause death or heart failure than the duration of 
ischemia, ST-segment resolution, TMPG and CFR after a median follow-up of 845 
days. 
However IMR remains an indirect measure for the coronary microvascular 
resistance and uses the inverse of transit time as a surrogate for flow. Furthermore, 
the manual injections of normal saline to obtain the transit times are prone to inter 
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and intra-observer variability and not all groups54, 55 have shown IMR could 
differentiate between patients with or without MVO.  
 
b) Hyperemic microvascular resistance (HMR)  
HMR is defined as the Pd divided by mean Doppler flow velocity at peak 
hyperemia simultaneously measured using a coronary guide wire with a combined 
pressure sensor and Doppler transducer61, 62 and measured in mm Hg cm-1 s. A 
guide wire with dual pressure and Doppler flow sensor is placed in the distal one 
third of the infarct-related artery. This dual - sensor guide wire has a Doppler crystal 
at the tip and a pressure sensor at 1.5 cm from the tip. At hyperemia, phasic 
coronary flow velocities are obtained from 3 consecutive cardiac cycles and used to 
calculate the average hyperemic flow velocity.  
The role of HMR in STEMI has been less well studied compared to IMR 
(summarized in the online appendix Table 1). The availability of a dual pressure and 
flow sensor wire allows simultaneous pressure and flow measurements within the 
coronary artery thereby making the measurement of HMR easier. HMR has been 
shown to be as good as CFVR and diastolic deceleration time at predicting regional 
wall motion recovery63 and the transmural extent of MI61, but superior to CFVR to 
predict LV remodeling at 8 months.64 In a small single-center study of 48 patients, an 
HMR value>2.5mm Hg cm-1 s has been shown to be indicative of MVO by CMR 
(sensitivity of 71% and specificity of 63%) and reduced myocardial blood flow on 
PET. In a larger cohort of 145 STEMI patients65, an HMR value>2.82 mm Hg cm-1 s 
was a strong predictor of a composite of death and re-hospitalization for heart failure. 
However, HMR was measured using the mean aortic pressure rather than the 
pressure distal to the coronary lesion in that study and more work with larger number 
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of patients are required to confirm the prognostic significant of HMR immediately post 
PPCI. 
HMR also remains an indirect measure for the microvascular resistance and 
uses half the peak Doppler-derived velocity as a surrogate for flow. Additionally, 
detecting an adequate flow signal using a guide wire tipped with both a Doppler flow 
and a pressure sensor can be technically difficult.  
 
c) Zero flow pressure (Pzf) 
Pzf is defined as the distal coronary pressure when hypothetically there would 
be no flow in the coronary artery. Data from several cardiac cycles are used to plot 
Pd against the peak velocity. There are automated algorithms that can then sample 
the resultant pressure–velocity loop at the mid-diastolic period of the averaged 
cardiac cycle. A regression can then be drawn automatically from the diastolic data 
points, and Pzf is the pressure at which this line crosses the x-axis. This is the 
extrapolated distal coronary pressure at which flow would cease in the infarct-related 
artery.40 It provides comprehensive assessment of the microvascular compartment 
as it assesses coronary flow over a range of pressures, irrespective of cardiac 
contractility and may reflect vascular tone.66 In the context of STEMI, it also provides 
information on the effect of the interstitial myocardial pressure on the coronary 
microcirculation.66 Pzf is derived from pressure-velocity loop analysis67 and it informs 
the operator on the effect of intra-ventricular and interstitial myocardial pressure 
(external forces) over collapsible elements (capillaries) of the microcirculation. 
Therefore, Pzf measured after PPCI can be expected to be dependent mainly on the 
extent of external microcirculatory compression by edema and IMH. After PPCI, 
microvascular impairment may be partly attributed to decrease in total cross-
sectional microvascular area by compressive effect generated by edema and/or IMH. 
Additionally, in patients with STEMI, increased diastolic filling pressures due to 
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increased cardiac muscle stiffness caused by cellular and interstitial edema may also 
decrease intramyocardial vascular capacitance and limits coronary flow in late 
diastole. Therefore, the transmitted increase in intra-cavity and interstitial pressures 
contribute to external compression of microcirculation and result in increased Pzf.  
In small proof-of-concept studies, Pzf was a better predictor of viability by 
FDG PET than CFVR (27 patients)67; was associated with higher left ventricular filling 
pressures (68 patients)66 and adverse LV remodeling (48 patients)68; and was a 
better predictor of chronic MI size by CMR than HMR and IMR (34 patients).40 
However, Pzf was not found to be superior to CFVR, Pzf and diastolic deceleration 
time in predicting the transmural extent of MI by CMR performed at 13 days (27 
patients).61 So far, only one study has evaluated Pzf and MVO by CMR and a cut-off 
value of 42mmHg for Pzf did not differentiate those with and without MVO.40  
As summarized in table 2, Pzf requires off-line post-processing and the 
automated algorithms for its interpretation are not widely available yet. Therefore this 
index currently remains a research tool. 
 
CURRENT APPLICATIONS  
IMR has already been used as a surrogate endpoint in several proof-of-concept 
studies aiming to improve the coronary microcirculation in reperfused STEMI patients 
(summarized in the online appendix Table 2). The impact of strategies such as 
intracoronary streptokinase administered immediately after PPCI 20, nicorandil69, 
sodium nitropruside70, distal protection device71, thrombus aspiration55 and a 
combination of intracoronary abciximab and aspiration thrombectomy51 on IMR has 
been investigated in small proof-of-concept studies and there are several other 
studies that are ongoing (summarized in the online appendix table 2). Of note, none 
of the randomized studies pre-selected patients based on high IMR values. 
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Hypothetically, in an ideal study, invasive coronary measurement with a reliable 
marker at the end of the PPCI procedure would identify those patients with MVO with 
high sensitivity and specificity. Given that MVO is due to a combination of factors, 
these patients would then be randomized to a combination therapy with intracoronary 
thrombolysis (to achieve patency of the microcirculation) and an intracoronary 
vasodilator with anti-inflammatory properties such as adenosine (which could be 
continued intravenously on the ward) or placebo. The primary endpoint of interest 
should ideally be hard clinical outcomes such as cardiovascular death and 
hospitalization for heart failure. However, such a study would require a large number 
of patients and endpoints such as the extent of IMH, MVO and MI size by CMR 3 
days later and adverse LV remodeling at 6 months could be used as surrogates.  
 
LIMITATIONS OF CURRENT INVASIVE MARKERS AND FUTURE DIRECTIONS 
Table 2 summarizes the limitations of the current invasive markers to assess the 
microcirculation discussed so far. Future studies should aim at addressing these 
limitations in the first instance. Some examples would be:  
To explore the possibility for an automated method (e.g. using a pump injector) to 
inject the 3ml of normal saline to minimize operator-related errors and improve inter-
observer and inter-site reproducibility when performing IMR measurement. 
Further validation work is required to assess the performance of HMR to detect MVO 
by CMR before it can be used to assess the effectiveness of therapies. Moreover, 
improvement in the delivery profile of the Doppler wire would increase the use of this 
technique in future studies.  
The derivation of Pzf is based on the extrapolation from the pressure-velocity loop 
and the analysis techniques are time-consuming and are not available for immediate 
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read-outs of Pzf. Therefore, more work remains to be done to make the analysis of 
fully automated and the Pzf read-outs to be immediately available at the time of 
PPCI, before it can be widely used. 
Limited data are available regarding the strength of diastolic deceleration time and 
systolic flow reversal to identify MVO when compared to IMR, HMR and Pzf. 
Therefore, further, adequately powered, comparative studies using these 
parameters, using a multi-center approach to facilitate recruitment are needed. 
These above steps would help to assess which of these markers would emerge as 
the most robust surrogate marker for predicting MVO at the end of the PPCI 
procedure. Early identification of these high-risk patients is important as already 
described above and early adjuvant intervention could then be started in the cardiac 
catheterization laboratory and administered via the intracoronary route and continued 
intravenously in the ward in needed. Therapies that may be beneficial in this setting 
would be glycoprotein IIb/IIIa inhibitors (e.g. abciximab21 to reduce platelet 
aggregation in the microcirculation); thrombolytics (e.g. half dose alteplase for lysis of 
distal embolization of thrombi); vasodilators (e.g. adenosine19, 72, nicorandil69 for 
spasm of the microcirculation due to release of vasoactive substances); and anti-
inflammatory agents (e.g. methylprednisolone73 to reduce reperfusion edema and 
relieve extrinsic compression of the microcirculation). Other treatments aiming to 
stabilize the endothelium with angiopoietin-1 or tyrosine kinase inhibitors13 may help 
to reduce extravasation of red blood cells and the development of IMH. Using this 
approach would also avoid any adjuvant strategies be given to those patients who 
are unlikely to have MVO, and minimize their exposure to potential adverse events.  
Figure 4 shows a hypothetical approach in future studies to identify and target those 
at high-risk at the end of the PPCI procedure using IMR as an example. Given that 
patients with an IMR of >40U has been shown to more likely have MVO56 and worse 
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outcomes 60 59, this value could be used as a cut-off.  Those patients with an IMR of 
>40U at the end of PPCI could then be targeted with further adjuvant therapies 
mentioned above and this approach may improve outcomes in this group of patients.  
 
CONCLUSION 
Invasive assessment of the coronary microcirculation at the time of PPCI is an 
exciting field that could provide us with the opportunity to interrogate the extent of the 
microvascular injury reliably in the cardiac catheterization laboratory at the end of the 
PPCI procedure despite having a patent infarct-related epicardial coronary artery. 
This approach would potentially identify those patients at high risk of MVO and target 
them with adjuvant therapies. However, more validation work remains to be done 
before one or a combination of these invasive markers described here could be used 
in therapeutic trials aiming to eventually improve outcomes in these patients. 
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Table 1: Non-invasive assessment and angiographic assessment of MVO 
 
Modality Comments Limitations 
ECG ST-segment resolution of <70% at 60 to 90 minutes 
post-reperfusion in the presence of a patent epicardial 
coronary is suggestive of MVO74. 
Inexpensive and portable. 
Discrepancies have been documented between coronary 
angiographic indices of reperfusion and ST-segment 
resolution75. 
There is a delay of at least one hour before it can be acquired 
for comparison. 
MCE Can detect the presence of MVO and can also quantify 
its severity. 
Inexpensive and can be portable. 
Several factors such as labour-intensive data acquisition, sub-
optimal images (especially of the lateral wall), difficulties with 
image interpretation, and safety concerns regarding the use of 
the micro-bubbles have hampered the widespread adoption in 
the clinical setting76 
CMR CMR can differentiate between early MVO using first 
pass perfusion or early gadolinium enhancement and 
late MVO by late gadolinium enhancement. 
CMR is also the gold standard to assess MI size, LV 
volumes and ejection fraction. 
CMR can also quantify the extent of MVO accurately 
and differentiate between hemorrhagic and non-
hemorrhagic MVO, thereby providing an additional layer 
of prognostic information77. 
Usually performed 2 to 7 days post-reperfusion when it may be 
too late to intervene. 
Not applicable to everyone – e.g. those with contra-indication to 
CMR will be excluded. 




MSCT MDCT performed immediately after PPCI could detect 
hypo-enhanced areas that were significantly associated 
with coronary angiographic no-reflow.78 
MDCT performed without contrast reinjection 
immediately after PPCI for the identification of 
heterogeneous enhancement could also predict the 
occurrence of MVO and adverse LV remodeling by 
CMR. 79 
This approach is logistically difficult to implement in most 
centers. 
Limited data from 2 studies so far and warrants further 
validation. 
TIMI flow A TIMI flow grade of <2 in the presence of a patent 
epicardial coronary artery is indicative of no-reflow.22 
Cannot be used to assess the microvascular circulation in those 
with TIMI flow 3.  
cTFC cTFC is a more robust method to assess the epicardial 
flow quantitatively23 and is more reproducible. 
Requires off line post-processing. 
MBG and TMPG MBG is a measure of maximum contrast intensity 
whereas TMPG is a measure of contrast washout time. 
MBG has also been shown to predict mortality in 
patients with TIMI 3 flow80 and may be more practical. 
A normal TMPG has been shown to be a superior 
marker of death than a TIMI flow of 3 in the thrombolytic 
era 24 
Capillary permeability, microvascular spasm and capillary 
resistance under resting conditions may influence these 
indices.27 
ECG: electrocardiography; MCE: myocardial contrast echocardiography; MDCT: contrast-enhanced multi-detector computed tomography; TIMI: 
TIMI: thrombolysis in myocardial infarction; cTFC: corrected TIMI frame count; MBG: myocardial blush grade; TMPG: TIMI myocardial 




Table 2: Definitions of invasive markers to assess the microvascular circulation 
 
 Comments Limitations 
CFVR  Defined as the ratio of hyperemic to resting 
coronary blood flow29 
 CFVR can also be derived using the 
thermodilution principle [CFVR = Tmn at rest/ 
Tmn at hyperemia]30   
 A ratio of ≥2.0 is considered normal  
 The Doppler flow velocity tracings may not be consistent 
from beat to beat and could be a source of variability. 
 CFVR is unable to distinguish between relative epicardial 
and microvascular contribution to total coronary 
resistance 
 CFVR is dependent upon hemodynamic factors (i.e., 
blood pressure, heart rate, etc.).  
 When using the thermodilution technique, manual 
injection of the saline can be a source of variability.  
 Requires the achievement of hyperemia. In the STEMI 
setting, using adenosine may be ineffective in those 
patients who may have consumed caffeinated products. 
IMR  Defined as Pd divided by the inverse of the 
Tmn during hyperemia, or more simply, Pd 
multiplied by the Tmn (mm Hg · seconds, or 
units [U])42  
 The wire sensor is usually positioned in the 
distal one third of the vessel (> 6cm from guide 
catheter tip)  
 The average of 3 transit times of 3ml of room 
temperature normal saline solution – the 
variability should be <20% - during peak 
hyperemia is used to calculate mean Tmn43 
 An IMR value < 25U is indicative of normal 
microvascular perfusion44.  
 IMR has been shown to be more reproducible 
 Manual injection of the saline can be a source of 
variability.  
 Requires the achievement of hyperemia. In the STEMI 
setting, using adenosine may be ineffective in those 
patients who may have consumed caffeinated products. 
28 
 
than CFR and to be independent of 
hemodynamic influences (pacing at 110 bpm, 
nitroprusside infusion or dobutamine infusion)41.  
 It is not affected by epicardial stenosis42  
 In the presence of collaterals, corrected IMR 
(cIMR) using the formula cIMR = Pa x Tmn x 
(Pd - Pw)/(Pa - Pw) is more accurate as this 
takes into account the contribution of collateral 
flow81 82.  
HMR  HMR is derived as the ratio of distal coronary 
pressure and hyperemic flow velocity61 and 
measured in mm Hg cm-1 s 
 A guidewire with dual pressure and Doppler 
flow sensor is placed in the distal one third of 
the infarct-related artery. 
 At hyperemia, phasic coronary flow velocity are 
obtained from 3 consecutive cardiac cycles and 
used to calculate the average hyperemic flow 
velocity 
 
 The Doppler flow velocity tracings may not be consistent 
from beat to beat and could be a source of variability. 
 Requires the achievement of hyperemia. In the STEMI 
setting, using adenosine may be ineffective in those 
patients who may have consumed caffeinated products. 
Pzf  Pzf is defined as the distal coronary pressure 
when hypothetically there would be no flow in 
the coronary artery.   
 Does not require hyperemia.  
 Data from several cardiac cycles are used to 
plot Pd against the peak velocity. There are 
automated algorithms that can then sample the 
resultant pressure–velocity loop at the mid-
diastolic period of the averaged cardiac cycle. A 
regression can then be drawn automatically 
from the diastolic data points, and Pzf is the 
 The Doppler flow velocity tracings may not be consistent 
from beat to beat and could be a source of variability. 




pressure at which this line crosses the x-axis. 
This is the extrapolated distal coronary 
pressure at which flow would cease in the 
infarct-related artery.40  
 
CFVR: coronary flow reserve; IMR: index of microvascular resistance; STEMI: ST-segment elevation myocardial infarction; Pd: distal pressure; 






Figure 1: Relationship between reperfusion injury (RI) and MVO 
The figure illustrates the different components of reperfusion injury (RI). Myocardial 
stunning and reperfusion arrhythmias are transient and self-limiting/ easily treated. 
However microvascular obstruction (MVO) and lethal myocardial reperfusion injury 
















Figure 2: The coronary circulation and factors contributing to the development 
of MVO 
This is an illustration of the coronary circulation. Coronary flow velocity reserve 
(CFVR) provides an indication of both the epicardial and microvascular circulation 
whereas index of microvascular resistance (IMR) / hyperemic microvascular 
resistance (HMR), diastolic deceleration time (DDT) and systolic flow reversal, and 
zero flow pressure (Pzf) interrogate the microvascular circulation in particular. 
This figure also illustrates the some of the factors contributing to the development of 
microvascular obstruction (MVO), namely external compression of capillaries by 
interstitial and/or cellular edema, by swollen cardiomyocytes and endothelial cells, 
cellular plugging, capillary damage with extravasation of red blood cells, coronary 









Figure 3: Microvascular obstruction by cardiovascular magnetic resonance 
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This is an example of a patient with an anterior STEMI with extensive areas of 
microvascular obstruction (MVO) (red arrows) on the late gadolinium enhancement 
images (a: mid ventricular short axis; b: 3-chamber; c: 4-chamber; d: 2-chamber 
views) of a cardiovascular magnetic resonance performed within a week of 
reperfusion by primary percutaneous coronary intervention (PPCI). Despite having a 
patent epicardial coronary at the end of the PPCI procedure with thrombolysis in 
myocardial flow 3 (normal flow), this patient suffered an extensive myocardial 
















Figure 4: A hypothetical approach to identify the patients at high-risk of 
developing MVO using IMR 
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This algorithm shows that index of microvascular resistance (IMR) could be used in 
those with thrombolysis in myocardial infarction (TIMI) flow 3 grade at the end of the 
primary percutaneous coronary intervention (PPCI) to further identify those who 
would benefit from further adjuvant intracoronary therapies. 
 
 
